Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.
Tempus AI shares were up 14%, to $36.42, after the company launched its FDA-approved in vitro diagnostic device, xT CDx. The healthcare technology company said Wednesday that, beginning today, xT CDx ...